Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The investigators major aim is to determine whether there is a difference in the retention of
zoledronic acid in multiple myeloma patients, compared to patients with breast cancer
metastasis to bone. In addition the investigators wish to analyze if the retention of
zoledronic acid is correlated to the extent of bone resorption/formation, and if there is a
tendency to changes in retention with sequential treatment.